Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans.
Reports of the association of Mycobacterium haemophilum with disease in humans have greatly increased. At least 64 cases have now been reported, with symptoms ranging from focal lesions to widespread, systemic disease. The organism is now known to cause primarily cutaneous and subcutaneous infection, septic arthritis, osteomyelitis, and pneumonitis in patients who are immunologically compromised and lymphadenitis in apparently immunocompetent children. Underlying conditions in the compromised patients have included AIDS; renal, bone marrow, and cardiac transplantation; lymphoma; rheumatoid arthritis; marrow hypoplasia; and Crohn's disease. Reports have originated from diverse geographic areas worldwide. The epidemiology of M. haemophilum remains poorly defined; there appears to be a genetic diversity between strains isolated from different regions. The organism is probably present in the environment, but recovery by sampling has not been successful. M. haemophilum has several unique traits, including predilection for lower temperatures (30 to 32 degrees C) and requirement for iron supplementation (ferric ammonium citrate or hemin). These may in the past have compromised recovery in the laboratory. Therapy has not been well elucidated, and the outcome appears to be influenced by the patient's underlying immunosuppression. The organisms are most susceptible to ciprofloxacin, clarithromycin, rifabutin, and rifampin. Timely diagnosis and therapy require communication between clinician and the laboratory.
Saubolle
M A
MA
Department of Pathology, Good Samaritan Regional Medical Center, Phoenix, Arizona 85006, USA.
Kiehn
T E
TE
White
M H
MH
Rudinsky
M F
MF
Armstrong
D
D
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000382:microbiology; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000382:microbiology; D001431:Bacteriological Techniques; D002648:Child; D002675:Child, Preschool; D002851:Chromatography, High Pressure Liquid; D001026:Coronary Artery Bypass / Q000009:adverse effects; D003424:Crohn Disease / Q000382:microbiology; D003470:Culture Media / Q000378:metabolism; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D008223:Lymphoma / Q000382:microbiology; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D009164:Mycobacterium Infections / Q000188:drug therapy / Q000276:immunology / Q000382:microbiology*; D018393:Mycobacterium haemophilum / Q000187:drug effects / Q000276:immunology / Q000302:isolation & purification / Q000472:pathogenicity*; D009171:Mycolic Acids / Q000032:analysis; D014180:Transplantation / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D003470:Culture Media; D009171:Mycolic Acids